Compare Citius Pharmaceuticals Inc (CTXR) vs VanEck Semiconductor ETF (SMH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs VanEck Semiconductor ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while VanEck Semiconductor ETF trades at $607.05. The key difference: VanEck Semiconductor ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | SMH | |
|---|---|---|
Market Cap | $14.64M | — |
Sector | Health | — |
52-Week High | $1.82 | $668.91 |
52-Week Low | $0.53 | $283.95 |
Enterprise Value | $10.86M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
SMH (VanEck Semiconductor ETF) trades at $585.62, down 4.22% over 24 hours amid a sector-wide sell-off. Technical indicators show a bearish trend with support at $579 and resistance at $589. Recent news highlights strong 2026 performance but notes high expectations and recent volatility in semiconductor stocks.
The ETF's outlook is clouded by near-term volatility, though long-term AI-driven demand for semiconductors remains a tailwind. Risks include sector concentration and macroeconomic pressures, but diversification within the chip industry offers a balanced exposure for investors seeking growth in technology infrastructure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About VanEck Semiconductor ETF
The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.
Read more on SMH →
